FibroGen Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
102,170.00
137,601.00
180,828.00
179,577.00
125,668.00
212,958
SG&A Expense
105,035.00
183,233.00
252,774.00
227,191.00
242,178.00
293,089
EBIT
7,949.00
50,102.00
77,625.00
53,654.00
122,609.00
86,693
Non Operating Income/Expense
156.00
16.00
3,121.00
2,628.00
6,433.00
11,568
Interest Expense
10,702.00
11,108.00
11,033.00
10,725.00
9,706.00
10,991
Pretax Income
14,943.00
59,504.00
85,537.00
61,751.00
125,882.00
86,116
Income Tax
-
-
242.00
71.00
321.00
304
Consolidated Net Income
14,943.00
59,504.00
85,779.00
61,680.00
126,203.00
86,420
Net Income
14,943.00
59,504.00
85,779.00
61,680.00
126,203.00
86,420
Net Income After Extraordinaries
14,943.00
59,504.00
85,779.00
61,680.00
126,203.00
86,420
Net Income Available to Common
14,943.00
59,504.00
85,779.00
61,680.00
126,203.00
86,420
EPS (Basic)
0.26
3.17
1.42
0.98
1.73
1.03
Basic Shares Outstanding
56,736.90
18,775.00
60,337.00
62,744.00
72,987.00
84,062
EPS (Diluted)
0.26
3.17
1.42
0.98
1.73
1.03
Diluted Shares Outstanding
56,736.90
18,775.00
60,337.00
62,744.00
72,987.00
84,062
EBITDA
2,865.00
45,632.00
71,946.00
47,614.00
116,510.00
80,131
Non-Operating Interest Income
3,552.00
1,690.00
-
-
-
-

About FibroGen

View Profile
Address
409 Illinois Street
San Francisco California 94158
United States
Employees -
Website http://www.fibrogen.com
Updated 07/08/2019
FibroGen, Inc. engages in the discovery, development, and commercialization of therapeutics to treat unmet medical needs. It focuses on fibrosis and hypoxia-induced factor biology to generate programs targeting therapeutic areas. The company was founded by Thomas B.